Safety and efficacy of high dose buprenorphine initiation in fentanyl positive emergency department patients

Authors

  • Siri Shastry Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, USA
  • Jennifer Love Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, USA
  • George Loo Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, USA; Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, USA
  • Alex F. Manini Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, USA; Division of Medical Toxicology, Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, Elmhurst Hospital Center, New York, USA
  • Clare O'Brien-Lambert Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, USA
  • Linda Wang Respectful and Equitable Access to Comprehensive Healthcare (REACH) Program, Division of General Internal Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA
  • Ethan Cowan Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, USA

DOI:

https://doi.org/10.18203/2349-3259.ijct20250130

Keywords:

BUP, Fentanyl, Precipitated withdrawal

Abstract

Background: The safety and efficacy of high dose buprenorphine (BUP) induction in fentanyl positive emergency department patients (high dose BUP) study includes two clinical trials funded through the helping to end addiction long-termSM initiative.  The study tests whether initiation and continuation of BUP at higher doses and over a shorter time period than currently recommended is safe, tolerable and effective.

Methods: Trial 1 is a head-to-head comparison of the safety, tolerability and feasibility of high dose BUP initiation (32 mg) and continuation (24 mg) as compared to standard dose BUP initiation (12 mg) and continuation (16 mg). Trial 2 is a small pilot multicenter randomized, double blind clinical trial in 80 participants, randomized 1:1, that will provide preliminary efficacy data. The primary outcome measure for trial 1 is the frequency of dose treatment-emergent adverse events (TEAEs) grade 3 (per common terminology criteria for adverse events v5.0 (CTCAE v5.0)), including but not limited to bradypnea <8, oxygen saturation<88% on room air and/or rescue naloxone administration. The primary outcome measure for trial 2 is the proportion of participants engaged in comprehensive addiction treatment at 7-days post ED initiation.

Conclusions: The results of these trials will provide crucial data on the safety, feasibility and efficacy of high-dose ED BUP initiation and continuation in fentanyl positive ED patients and inform incorporation of high-dose BUP initiation into ED care for patients with OUD. 

Trial registration: ClinicalTrials.gov ID: NCT05589181

Metrics

Metrics Loading ...

References

Jones CM, Einstein EB, Compton WM. Changes in Synthetic Opioid Involvement in Drug Overdose Deaths in the United States, 2010-2016. JAMA. 2018;319(17):1819-21. DOI: https://doi.org/10.1001/jama.2018.2844

Jeffery MM, Stevens M, D'Onofrio G, Melnick ER. Fentanyl-Associated Overdose Deaths Outside the Hospital. N Engl J Med. 2023;389(1):87-8. DOI: https://doi.org/10.1056/NEJMc2304991

Centers for Disease Control and Prevention. Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic. Available at: https://emergency.cdc.gov/han/2020/han00438.asp. Accessed on 12 March 2024.

Lee JD, Friedmann PD, Boney TY, Hoskinson RA, McDonald R, Gordon M, et al. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial. Contemp Clin Trials. 2015;41:110-7. DOI: https://doi.org/10.1016/j.cct.2015.01.005

Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;2009(3):CD002209. DOI: https://doi.org/10.1002/14651858.CD002209.pub2

Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2014(2):CD002207. DOI: https://doi.org/10.1002/14651858.CD002207.pub4

Sullivan M, Bisaga A, Pavlicova M, Choi CJ, Mishlen K, Carpenter KM, et al. Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine. Am J Psychiatry. 2017;174(5):459-67. DOI: https://doi.org/10.1176/appi.ajp.2016.16050548

Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. DOI: https://doi.org/10.1136/bmj.j1550

Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55(5):569-80. DOI: https://doi.org/10.1038/clpt.1994.71

Dematteis M, Auriacombe M, D'Agnone O, Somaini L, Szerman N, Littlewood R, et al. Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opin Pharmacother. 2017;18(18):1987-99. DOI: https://doi.org/10.1080/14656566.2017.1409722

Kuhlman JJ, Lalani S, Magluilo J, Levine B, Darwin WD. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol. 1996;20(6):369-78. DOI: https://doi.org/10.1093/jat/20.6.369

Volkow ND, Collins FS. The Role of Science in Addressing the Opioid Crisis. N Engl J Med. 2017;377(4):391-4. DOI: https://doi.org/10.1056/NEJMsr1706626

Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35(2):253-9. DOI: https://doi.org/10.1080/02791072.2003.10400007

Guo CZ, D'Onofrio G, Fiellin DA, Edelman EJ, Hawk K, Herring A, et al. Emergency department-initiated buprenorphine protocols: A national evaluation. J Am Coll Emerg Physicians Open. 2021;2(6):e12606. DOI: https://doi.org/10.1002/emp2.12606

Shearer D, Young S, Fairbairn N, Brar R. Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series. Drug Alcohol Rev. 2022;41(2):444-8. DOI: https://doi.org/10.1111/dar.13394

Silverstein SM, Daniulaityte R, Martins SS, Miller SC, Carlson RG. "Everything is not right anymore": Buprenorphine experiences in an era of illicit fentanyl. Int J Drug Policy. 2019;74:76-83. DOI: https://doi.org/10.1016/j.drugpo.2019.09.003

Antoine D, Huhn AS, Strain EC, Turner G, Jardot J, Hammond AS, et al. Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone. Am J Addict. 2021;30(1):83-7. DOI: https://doi.org/10.1111/ajad.13069

Comer SD, Cahill CM. Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment. Neurosci Biobehav Rev. 2019;106:49-57. DOI: https://doi.org/10.1016/j.neubiorev.2018.12.005

Huhn AS, Hobelmann JG, Oyler GA, Strain EC. Protracted renal clearance of fentanyl in persons with opioid use disorder. Drug Alcohol Depend. 2020;214:108147. DOI: https://doi.org/10.1016/j.drugalcdep.2020.108147

Bisaga A. What should clinicians do as fentanyl replaces heroin. Addiction. 2019;114(5):782-3. DOI: https://doi.org/10.1111/add.14522

Hoot NR, Aronsky D. Systematic review of emergency department crowding: causes, effects, and solutions. Ann Emerg Med. 2008;52(2):126-36. DOI: https://doi.org/10.1016/j.annemergmed.2008.03.014

Greenwald MK, Herring AA, Perrone J, Nelson LS, Azar P. A Neuropharmacological Model to Explain Buprenorphine Induction Challenges. Ann Emerg Med. 2022;80(6):509-24. DOI: https://doi.org/10.1016/j.annemergmed.2022.05.032

Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2020. Available at: https://store.samhsa.gov/sites/default/files/pep21-02-01-002.pdf. Accessed on 12 December 2024.

Pasero C. Assessment of sedation during opioid administration for pain management. J Perianesth Nurs. 2009;24(3):186-90. DOI: https://doi.org/10.1016/j.jopan.2009.03.005

Fleming MF, Barry KL. A three-sample test of a masked alcohol screening questionnaire. Alcohol Alcohol. 1991;26(1):81-91. DOI: https://doi.org/10.3109/10826089109062153

Downloads

Published

2025-01-28

How to Cite

Shastry, S., Love, J., Loo, G., Manini, A. F., O’Brien-Lambert, C., Wang, L., & Cowan, E. (2025). Safety and efficacy of high dose buprenorphine initiation in fentanyl positive emergency department patients. International Journal of Clinical Trials, 12(1), 11–20. https://doi.org/10.18203/2349-3259.ijct20250130